Description: Lumos Diagnostics Holdings Limited operates as an integrated developer and manufacturer of point-of-care (POC) diagnostic tests. The company develops and manufactures proprietary and in-licensed POC diagnostic tests. Its products include FebriDx, a test that differentiates between bacterial and viral respiratory infections; ViraDx, a combined COVID/Influenza test for acute respiratory infections; and CoviDx, an antigen test for COVID-19. The company also engages in the contract research and development services specialized in the innovation, development, commercialization, and manufacturing of point-of-care diagnostic solutions for clinical and consumer applications. It offers its products through distributors primarily in the North American and European markets. The company was founded in 2004 and is headquartered in Melbourne, Australia.
Home Page: lumosdiagnostics.com
2724 Loker Ave West
Carlsbad,
CA
92010
United States
Phone:
855 586 6739
Officers
| Name | Title |
|---|---|
| Mr. Douglas Ward | CEO, MD & Director |
| Mr. Barrie Lambert | Chief Financial Officer |
| Dr. Sacha Dopheide Ph.D. | Chief Technology Officer |
| Ms. Jennifer Christiansen | Vice President of Corporate Marketing & Communications |
| Ms. Sarah Glubka | Senior Director of Human Resources |
| Mr. Paul Kase | Senior Vice President of Commercial Operations |
| Ms. Tracy Weimar BA, MBA | Company Secretary |
Exchange: PINK
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.8955 |
| Price-to-Sales TTM: | 1.8492 |
| IPO Date: | |
| Fiscal Year End: | June |
| Full Time Employees: | 0 |